DISCUSSION PAPER SERIES

DP15386

EFFICIENT POLICY INTERVENTIONS IN AN EPIDEMIC

Piero Gottardi and Alberto Bisin

INDUSTRIAL ORGANIZATION

PUBLIC ECONOMICS



EFFICIENT POLICY INTERVENTIONS IN AN EPIDEMIC

Piero Gottardi and Alberto Bisin

Discussion Paper DP15386 Published 19 October 2020 Submitted 17 October 2020

Centre for Economic Policy Research 33 Great Sutton Street, London EC1V 0DX, UK Tel: +44 (0)20 7183 8801 www.cepr.org

This Discussion Paper is issued under the auspices of the Centre's research programmes:

- Industrial Organization
- Public Economics

Any opinions expressed here are those of the author(s) and not those of the Centre for Economic Policy Research. Research disseminated by CEPR may include views on policy, but the Centre itself takes no institutional policy positions.

The Centre for Economic Policy Research was established in 1983 as an educational charity, to promote independent analysis and public discussion of open economies and the relations among them. It is pluralist and non-partisan, bringing economic research to bear on the analysis of medium- and long-run policy questions.

These Discussion Papers often represent preliminary or incomplete work, circulated to encourage discussion and comment. Citation and use of such a paper should take account of its provisional character.

Copyright: Piero Gottardi and Alberto Bisin

EFFICIENT POLICY INTERVENTIONS IN AN EPIDEMIC

Abstract

In the context of an epidemic, a society is forced to face a complex system of externalities in consumption and in production. Command economy interventions can support Efficient allocations at the cost of severe information requirements. Competitive markets for infection rights (alternatively, Pigouvian taxes) can guarantee instead efficiency without requiring direct policy interventions on the activity of agents and firms. We demonstrate that this is the case also when the infections cannot be associated to the activities which originated them; and moral hazard then ensues. Finally, we extend the analysis to situations where governments have only incomplete information regarding the values of the parameters of the infection process or of firms' production processes.

JEL Classification: H23, D62, D82

Keywords: Epidemic, Externalities, Pigouvian Taxes, infection rights

Piero Gottardi - piero.gottardi@essex.ac.uk University of Essex and CEPR

Alberto Bisin - alberto.bisin@nyu.edu New York University and CEPR

Acknowledgements We wish to thank Ben Moll, Flavio Toxvaerd and GianLuca Violante for helpful discussions.

Efficient Policy Interventions in an Epidemic^{*}

Alberto Bisin $(NYU)^{\dagger}$ P

Piero Gottardi (Essex)[‡]

October 12, 2020

Abstract

In the context of an epidemic, a society is forced to face a system of externalities in consumption and in production. Command economy interventions can support Efficient allocations at the cost of severe information requirements. Competitive markets for *infection rights* (alternatively, Pigouvian taxes) can guarantee efficiency without requiring direct policy interventions on socio-economic activities. We demonstrate that this is the case also when the infections cannot be associated to the activities which originated them. Finally, we extend the analysis to situations where governments have only incomplete information regarding the values of the parameters of the infection or of firms' production.

^{*}We wish to thank Ben Moll, Flavio Toxvaerd and GianLuca Violante for helpful discussions. [†]Department of Economics, New York University; alberto.bisin@nyu.edu

[‡]Department of Economics, University of Essex; piero.gottardi@essex.ac.uk.

1 Introduction

A society hit by an epidemic is forced to face a complex system of externalities in consumption and in production. The epidemic diffuses by social contacts between agents, which are an essential by-product of production and consumption-leisure activities. Rational agents and profit maximizing firms, in this society, will take into account the individual costs of the infections generated by their choices but will not internalize the externalities of their actions: hence firms will over-produce, agents will over-consume, and in turn infections will be more widely spread, with respect to the efficient level.

Policy interventions will generally be necessary to design efficient mechanisms to limit infections while allowing for some economic activity. In the course of the SARS-Cov-2 epidemic the most frequently adopted (non-pharmaceutical) policy interventions were partial lockdowns; that is, command economy interventions directly restricting firms and agents' behavior, selecting which firms produce how much and which agents are allowed to engage in consumption-leisure activities and how much so. In several instances, activities have been ranked in terms of their infectiousness and their opening staggered as the epidemic slowed-down. But command economy interventions are not the only possible mechanism to implement efficient allocations in general, nor are the mechanism with minimal information requirement to be implemented. As for other types of externalities, e.g., pollution, markets for the rights to externality-producing activities, or alternatively, Pigouvian taxes, can be set-up which induce agents and firms to consume and produce efficiently. The cost of infection rights or the Pigouvian taxes imposed on economic activities induce individuals and firms to limit more the kinds of activities that are more likely to produce infections.

In this paper we study the design of these alternative mechanisms, say markets for *infection rights* or Pigouvian taxes, in the context of a simple model of a society hit by an epidemic. We determine the conditions under which these mechanisms decentralize efficient allocations in this environment. We characterize the properties of these mechanisms. In particular, we characterize the equilibrium prices of infection rights or, equivalently, the optimal Pigouvian taxes on economic activities. We study in detail the information requirements for their implementation. We demonstrate that efficiency can be attained even when infections cannot be associated to the activities which originated them, that is, to the production choices of specific firms or to the consumption-leisure activities of specific consumers. Finally, we extend the analysis to situations where governments have only incomplete information regarding the values of the parameters of the infection process or of firms' production processes. In this case efficiency cannot be attained, and we compare the welfare properties of i) setting the quantity of infection rights to be traded, ii) setting their prices or taxes; iii) command economy interventions.

A few very recent papers have introduced rational, optimizing agents in the framework of epidemiological models, highlighting the importance of individual behavior in response to policy interventions and the trade-offs between health and economic costs; see e.g., Acemoglu et al. (2020), Alvarez et al. (2020), Argente et al. (2020), Atkeson (2020), Bisin and Moro (2020), Eichenbaum et al. (2020), Toxvaerd (2020). In particular, closer to our focus in this paper, Rowthorn and Toxvaerd (2020) provide a theoretical analysis of taxes and subsidies which decentralize efficient allocations in an epidemiological model of the dynamics of an infection. Kaplan et al. (2020) provide a quantitative analysis, in an heterogenous agent economy, of the distributional effects of taxes on production and consumption activities that generate infections. Also, Bethune and Korinek (2020) study the externalities that arise in such framework, by providing a quantitative assessment of the individual and social cost of infections. Farboodi et al. (2020) focus on an environment where, like in our set-up, agents partially internalize the individual but not the social costs of these activities. The novelty of our analysis consists in our emphasis on the characterization and informational requirements of measures that do not rely on the direct control of some individual choices but rather on the design of additional markets (or taxes) which can induce agents to internalize the social costs of their behavior.¹

2 Economy

In this section we first describe a simple abstract society hit by an epidemic. We consider a static environment to highlight in a stark manner the role of various sources of externality in the epidemic. We extend the analysis in Section 4, to allow for heterogeneity of agents and firms and for multiple sectors.

Agents. The society is populated by L ex-ante identical (representative) agents and a single (representative) firm. Each agent receives utility from consumption of a private good c and of a consumption-leisure good l which requires social interactions to be enjoyed. Each agent can be infected while interacting socially, with probability I_l , and/or at work, with probability I_h . Let $I = I_l + I_h$.² The probability of infection I_l increases with the level of the agent's consumption-leisure activity l; it also

¹This is in line with the approaches developed for other kinds of externalities, pioneered by Lindahl (1919), Pigou (1920), Coase (1960), Arrow (1969), Baumol (1972). See, for instance, Dales (1968) for pollution, Bisin and Gottardi (2006) for consumption externalities due to adverse selection.

 $^{^{2}}$ We assume that whether an agent is infected and whether he/she was infected at work or in the course of his consumption-leisure activities is publicly observed. We shall relax this assumption in Section 4.3, when we discuss how to extend our analysis to allow for various informational asymmetries regarding infections.

increases with the average value of l in the population, l:

$$I_l = \delta(l, \bar{l}), \text{ with } \partial \delta / \partial l > 0, \ \partial \delta / \partial \bar{l} > 0.^3$$

Agents supply labor inelastically, taking as given the probability of infection at work, I_h , which is determined by the firm's choices. The representative consumer's utility function is

$$u(c,l) - \beta I,$$

with u(.) increasing and concave and β constituting the agent's disutility of becoming infected (for a given level of treatment, as specified below by η).

Firms. Each firm produces the private consumption good with the production function

$$Y = AL_h(1 - I)$$

where Y is output, L_h is the quantity of labor employed in the firm and $L_h I$ is the number⁴ of workers in the firm who become infected and are then assumed to be unproductive.

The probability of a worker of being infected at work is given by

$$I_h = \gamma(1-a),$$

where $\gamma > 0$ and *a* denotes social distancing and other abatement measures the firm can employ, at costs $C(a, L_h)$ (increasing and convex in $a, L_h)^5$, to reduce infection at work of all workers employed. Firms' profits are $\pi = Y - wL_h - C(a, L_h)$, where *w* is the market wage taken as given by the firm.⁶

Public sector. Infections need be treated by the health care sector, which we assume is public and run by the government. Public expenditures in health care are^{7}

$$g = \eta (I_h + I_l)L,$$

³We also assume that $\partial^2 \delta / \partial l \partial \bar{l} \geq 0$, introducing the possibility of a strategic complementarity in agents' consumption-leisure choices.

⁴Strictly speaking, the expected number.

⁵Except when the analysis is extended to the case of firms with heterogeneous technologies, in Section 4.1, abatement costs can also be considered linear in L_h , so the technology exhibits constant returns to scale.

⁶The consumption good is assumed to be the numeraire.

⁷The analysis could be easily extended to the case where the level of treatment, captured by η , here exogenous, is also a choice variable (which in turn affects β).

and are financed by lump-sum taxes T levied on consumers.

Competitive Equilibrium At a Competitive Equilibrium, i) each agent maximizes his/her utility, by choice of c, l, for given π , I_h , w, T, \overline{l} subject to the budget constraint $c = \frac{\pi}{L} + w - T$; ii) each firm maximizes profits by choice of a, L_h , for given w, I_l ; iii) the government balances its budget; iv) markets clear; v) the externality in social interaction satisfies the consistency condition, $l = \overline{l}$.⁸

Both consumers and firms face a direct disutility from the infections generated by their consumption-leisure and their production and abatement decisions. A higher level of consumption-leisure l in fact increases social interactions and probability of infection I_l and this in turn generates a higher disutility for the individual βI_l . Similarly, a firm by lowering its abatement measures saves on costs but also suffers losses because the increase in I_h induced by the reduction in a reduces the fraction of its workers who are productive. But consumption-leisure and abatement decisions also give rise to externalities faced by the society in an epidemic: i) each consumer does not take into account the fact that his/her consumption-leisure activity also increases the probability that other individuals are infected, via the effect of his choice on \overline{l} and hence on $\delta(l,\overline{l})$; ii) he/she also does not consider the fact that this activity negatively affects the firms' productivity, by reducing the fraction of productive workers; iii) furthermore, the consumer ignores that infections entail another cost for the society, given by the health costs η incurred by the government to cure infected agents. Analogously, in the production sector, each firm does not consider the fact that: iv) agents infected at work face a utility costs β and v) also produce a societal health cost η .

Due to these externalities, competitive equilibria are not efficient. Efficient allocations are those which maximize social welfare subject to feasibility and the infections equations $I_l = \delta(l, l)$, $I_h = \gamma(1 - a)$. In our simple economy social welfare coincides with the representative agent utility, $u(c, l) - \beta(I_l + I_h)$, and hence the economy admits a unique Efficient allocation. The Efficient allocation induces an efficient level of infections in the society $(I_l + I_h) L$, which is lower than the level of infections at the competitive equilibrium.

3 Market Implementation of the Efficient allocation

In this section we show how the Efficient allocation can be implemented via markets, designed to induce firms to produce - and consumers to choose consumption-leisure activities (with associated social interactions) - efficiently.

⁸All complete formal definitions are in the Appendix.

We shall discuss several different implementation mechanism, but it is convenient to set *markets for infection rights* as the benchmark.

3.1 Markets for infection rights

The institutional market design is as follows:

- Each agent engaging in consumption-leisure activities is mandated to buy a right per unit of probability of infection I_l induced by his/her activities;
- Each firm producing Y units and choosing abatement a is mandated to buy a right per unit of probability of infection I_h induced by its own choices.

Let q_l denote the price of these *infection rights* for consumption-leisure activities and q_h the price of *infection rights* for production.⁹

Competitive equilibrium with infection rights. A Competitive equilibrium with infection rights is a competitive equilibrium as previously defined but i) agents and firms face the cost of infection rights, respectively $q_l I_l$ and $q_h I_h L_h$ in their budget constraints and profits; ii) the government chooses the supply of infection rights H_l , H_h and its revenue is augmented by the value of those rights; iii) markets for infection rights also clear, $I_h L = H_h$, $I_l L = H_l$.

It is now straightforward to prove that, conditionally on the government supplying tradable infection rights H_l , H_h in an amount equal to the efficient level of infections, while letting prices clear these markets, the Efficient allocation obtains at a competitive equilibrium.

Proposition (Efficiency of equilibria). Suppose the government chooses a supply of infection rights H_l , H_h equal to the efficient infections I_lL , I_hL . Then the Efficient allocation obtains at the Competitive equilibrium with infection rights.

The proof of the above decentralization result is by construction.¹⁰ That is, we find prices q_l, q_h , such that the levels of consumption and social interaction c, l chosen by individual consumers, and of production and abatement y, a chosen by firms, and the induced infection rates I_l, I_h , are efficient. The revenue that is generated by the sale of the infection rights is then used to fund the health expenditures incurred by the government, with the difference between the two set equal to a lump sum tax -

⁹Notice that this institutional design of markets for infection rights requires that both the individual probability of getting infected as well as whether an infection occurs at work or in a consumption-leisure activity are publicly observable in the economy. We will relax both conditions later.

¹⁰All proofs are in the Appendix.

or transfer if negative - T on consumers. The key step in the argument of the proof is then the characterization of the values of these prices and transfers, stated in the following result.

Proposition (Efficiency of equilibrium - prices). At the Efficient Competitive equilibrium with infection rights, the prices of the rights q_h and q_l are, respectively,

$$q_h = \frac{\beta}{\partial u/\partial c} + \eta. \tag{1}$$

$$q_l = (\eta + A) + (\eta + A)\Delta + \frac{\beta}{\partial u/\partial c}\Delta$$
⁽²⁾

where $\Delta = \left[\frac{\partial \delta(l,\bar{l})/\partial \bar{l}}{\partial \delta(l,\bar{l})/\partial l}\right]_{\bar{l}=l}$ is the multiplicative effect of each agent's choice l on other agents' infections (via the effect on the average value \bar{l}), evaluated at the equilibrium $\bar{l} = l$. Furthermore, the lump-sum tax T is negative:

$$T = -I_l L(q_l - \eta) - I_h L(q_h - \eta).$$
(3)

The expressions of the prices of infection rights q_l, q_h allow to clearly see how the various kinds of externalities described in the previous section can be internalized by markets for those rights. The price of the rights for the firm, q_h , is equal to the marginal utility cost of infection for individuals, $\frac{\beta}{\partial u/\partial c}$ plus the marginal costs for the health care system η . The additional marginal cost of an infection at work, given by the decrease in the productivity of the workforce, does not enter the price of infection rights q_h because it is already internalized in the firm's production and abatement decisions. Turning then to the price of the rights for the agent, q_l , we see it is composed of three terms. The first, $\eta + A$, represents the marginal costs of an infection for the health care system and for the firms (as a productivity loss). The second and third terms capture the additional marginal costs due to the externality in infections, generated by the effect of each agent's consumption-leisure choice l (which determines the average value \overline{l}) on other agents' infectional costs borne by the health care system and the firms, while the third term, $\frac{\beta}{\partial u/\partial c}\Delta$, encodes the component given by utility costs of infected agents.

Finally, the revenue raised by the government at equilibrium by the sale of infection rights at prices q_l, q_h is higher than the costs borne by the health care system. This is due to the fact that, as explained above, the prices of infection rights at an efficient equilibrium do more than just allow consumers and firms to internalize the health costs of infections, as they also internalize additional utility and production costs. The surplus for the government is then rebated back to consumers through the lump-sum subsidy -T (a negative lump-sum tax in our notation), to support the Efficient allocation.

3.2 Other market implementation mechanisms

Some subtle and important issues arise in the design of markets for infection rights. We discuss here some alternative market mechanisms which implement the Efficient allocation.

Market for infection rights and insurance. In the design of markets for infection rights introduced in the previous section it is the probability of being infected that is being priced. But this mechanism is equivalent to one where i) agents and firms are required to buy infection right only if they and their workers, respectively, are infected; but ii) markets exists to ex-ante insure this risk, at fair prices $q_l I_l$ and $q_h I_h L_h$, respectively, for agents and firms.

Markets for infection rights - price-setting. An alternative policy design for the same structure of markets is given by the government setting the prices of these rights at a given level and standing ready to supply the amount requested at these prices by consumers and firms. If prices q_l , q_h are set at the level given by (1), (2), the Efficient allocation is implemented.

Pigouvian taxes. An alternative interpretation/implementation of markets for infection rights consists in the introduction of a Pigouvian tax scheme on the activities generating infections.¹¹ The case in which taxes are levied directly on the infections generated by production and consumption-leisure choices is just a simple reformulation of the requirement to acquire infection rights. In this case, the tax rates simply coincide with the prices of rights. But it is similarly straightforward to design a tax scheme whose base is the consumption-leisure activities of each agent and the production of each firm, with rebates based on the firm's abatement choices.

4 Informational requirements for efficiency

In this section we argue that markets for infection rights (and hence Pigouvian taxes) are generally superior to command economy interventions, in that they require less information to be implemented. To this end, we study the informational requirements necessary to achieve efficiency in a society hit by an epidemic. We compare

¹¹The Pigouvian qualification on the tax scheme indicates that taxes are imposed on agents and firms for engaging in activities that create negative externalities for society.

the informational requirements necessary for command economy interventions with those necessary to implement markets for infection rights. We also compare the relative informational requirements associated to the different institutional designs of markets for infection rights we discussed.

Command economy interventions require information on the technology of firms, the preferences of agents and the infection process; notably, on the productivity parameter A, the abatement cost function $C(a, L_h)$, the infection at work spread parameter γ , the agents' utility function u(c, l) and preference parameter β , the infection in leisure function $\delta(l, l)$, and the health cost parameter η . The decentralization result through markets for infection rights requires instead the government to choose the efficient supply of infection rights, that is, "the supply of infection rights H_l, H_h corresponding to the resulting infections $I_h L, I_l L$ at the Efficient allocation". In the simple environment we considered in the previous sections, the informational requirements of determining this level of the supply are not too different from those of implementing command economy interventions. The advocated superiority of introducing markets for infection rights over command economy interventions rests mostly on the consideration of richer and more complex economies, where agents and firms are heterogeneous and/or the values of preferences and productivity parameters are only privately known. In the next sections, we extend the analysis to such richer environments and discuss the associated informational requirements.

4.1 Heterogeneity and multiple sectors

Consider first adding technological heterogeneity to firm production. In particular, suppose there are different types of firms, indexed by j = 1, 2, ..., J, and characterized by different technological parameters A_h^j, γ_h^j , for production and infection at work, and different abatement cost functions $C_h^j(a_h^j, L_h^j)$. In this case, command economy interventions can still implement the Efficient allocation, whose definition is aptly and straightforwardly extended. But they require policy makers to set production, labor demand, and abatement y_h^j, L_h^j, a_h^j for each firm j. In other words, the policy maker needs knowledge of each firm's type j and its technological configuration $A_h^j, \gamma_h^j, C_h^j(a_h^j, L_h^j)$. The implementation of markets for infection rights, on the other hand, only requires the knowledge of the distribution in the economy of the configurations $\gamma_h^j, A_h^j, C_h^j(a_h^j, L_h^j)$, in order to determine the level of the total supply of rights for infection at work, a much smaller requirement.

The next is a fundamental but easily shown point. At the Competitive equilibrium with infection rights, whose definition is also straightforwardly extended, all the different firms will be required to trade infection rights, but the price of infection rights q_h remains determined as in (1). Indeed, while in this economy production, infection, and abatement parameters are heterogeneous across firms, q_h does not depend on these parameters. As a consequence, the design of any mechanism relying on markets for infection rights or Pigouvian taxes does not require information on the technological parameters of each individual firm, but just the knowledge of their distribution in the economy to calculate the efficient amount of infection rights to supply or their sale prices/taxes. Importantly, however, even though the price of infection rights is the same for all firms, the total cost of infection rights borne by any firm will depend on its own production, infection, and abatement parameters. In particular, firms characterized by a relatively lower productivity A_h^j or a higher marginal cost of abatement $C_{h,1}^j(a_h^j, L_h^j)$ are likely to choose a lower abatement¹² and to have so a higher probability of infection I_h^j . These firms need then to buy a larger amount of rights (per worker employed), or the Pigouvian tax revenue levied on - these firms is higher.¹³

Our findings then show that firms and/or sectors whose productivity loss associated to remote work is relatively small, that is, whose abatement costs are low, face a lower expenditure for the purchase of infection rights (or Pigouvian taxes) at equilibrium. On the other hand, firms and/or sectors relatively concentrated in dense cities whose workers e.g., are likely to use public transportation, will have a higher expense for infection rights (or Pigouvian taxes).

Consider now extending the analysis to allow for heterogeneity in agents' preferences and infectiveness in consumption-leisure activities. In particular, suppose there are L types of individuals, indexed by i = 1, 2, ..., L, characterized by different preferences $\beta^i, u^i(c, l)$, different infectiveness $\delta^i(l, \bar{l})$, and different health care costs, η_i . With heterogeneous agents distributional issues arise as Efficient allocations are a whole frontier, not a single point. These issues can only partly be addressed allowing for lump-sum taxes/subsidies T^i indexed by i, as the heterogeneity of the disutility β^i of getting infected also affects the magnitude of the externality which needs to be internalized. In the case of utilitarian welfare, where all agents are equally weighted, the expression for the price of infection rights, once we suitably extend the definition of the Competitive equilibrium with infection rights, becomes:¹⁴

$$q_l^i = A + \eta_i + \sum_{f=1}^{L} (A + \eta_f) \frac{\frac{1}{L} \frac{\partial \delta^f}{\partial l_i}}{\frac{\partial \delta^i}{\partial l_i}} + \sum_{f=1}^{L} \frac{\beta_f}{\frac{\partial u^i}{\partial c}} \frac{\frac{1}{L} \frac{\partial \delta^f}{\partial l_i}}{\frac{\partial \delta^i}{\partial l_i}}, \ i = 1, .., L$$
(4)

In (4) we see that, relative to the previous expression, (2), (i) the multiplicative effect

¹²The size of the employment L_h^j in these firms will be smaller and this in turn affects the level of the marginal cost of abatement. The overall effect on the (efficient) equilibrium choice of abatement requires to take this effect also into account.

¹³In contrast, the effect of a more infectious technology (with higher γ_h^j) is ambiguous, since firms operating such technology choose a higher level of abatement and hence the overall effect on infections could go either way.

¹⁴See the Appendix for details.

of individual choices on other agents' infections (generated by social interaction activities) now varies across individuals: $\Delta^{i} = \left[\frac{\sum_{f=1}^{L} \frac{\partial \delta^{i} / \partial \bar{l}}{L}}{\partial \delta^{i} / \partial l_{i}}\right],$ (ii) this effect is weighted with the heterogenous utility and health costs across individuals. Furthermore, the term on the right hand side of (4) varies with the agent's type *i* so that, differently from the case of technological heterogeneity, one single market for infection rights does not suffice to implement an Efficient allocation and personalized (type-indexed) prices (or Pigouvian taxes) q_{l}^{i} are required.

These prices/taxes are higher for agents whose relative marginal health care costs η^i are higher and who are relatively more infective, in the sense that they have a larger multiplicative effect Δ^i (or equivalently, for whom the effect of the agent's consumption-leisure on own infection is smaller). The same is true for agents with relatively lower marginal utility for consumption $\partial u^i / \partial c$, as for instance richer agents: a higher price is needed to induce them to internalize their externalities. On the other hand, the individual own cost of getting infected, β^i , does not affect the price of infection rights (or Pigouvian taxes), as its effect is internalized in the agent's choice of consumption-leisure activities.¹⁵

Nonetheless, and similarly to the case with technological heterogeneity, the total payment/tax required for agents depends not only on the price but also on the amount of rights purchased, that is on the own infection probability I_l^i . This amount will be higher for agents with lower β^i and $\partial u^i/\partial c$, because such agents, other things equal, will choose a higher value of l and hence have a higher infection probability in equilibrium.¹⁶

Personalized prices of infection rights (or Pigouvian taxes) with heterogenous consumers clearly impose stronger informational requirements to design markets for infection rights, easily satisfied if, e.g., the heterogeneity depends primarily on agents' demographic characteristics, generally observable. In that case the analysis above implies that, for instance, younger agents, with lower health care costs of infection η^i , should face lower prices/taxes.

Similar results obtain if we extend the analysis to allow for a variety of consumptionleisure activities, for which the magnitude of the external effect on the infection of other agents is different. This can be captured by replacing the average level \bar{l} in the expression of $\delta^i(l, \bar{l})$ for all *i* with a weighted average of the consumption-leisure choices of all individuals, with weights v_i reflecting the intensity of interaction with

¹⁵The weighted average of the utility cost of all individuals still appears in (4) because it contributes to determine one of the effects of the externality in infections due to agents' consumptionleisure choices.

¹⁶The effect of the marginal probability of getting infected $\frac{\partial \delta^i}{\partial l_i}$, on the other hand, is ambiguous, for reasons analogous to what we saw for γ^j in the case of the firms. The lower is $\frac{\partial \delta^i}{\partial l_i}$, other things equal, the higher is l_i , so the effect on I_i^i is ambiguous, while q_i^i , as we saw, is also higher.

other agents associated with the kind of consumption-leisure activity that is chosen by an agent. For instance, a high weight v_i may reflect the centrality of the individual in the network of social interactions, or the agent's strong preference for participating in large events like concerts or sport gatherings. The higher v_i , the higher the multiplicative effect Δ^i and the higher the price of rights (or the Pigouvian tax) faced by an individual.

We summarize our findings in the following:

Proposition (Prices of infection rights/Pigouvian taxes - with heterogeneity). Firms operating technologies with lower productivities or higher (marginal) costs of abatement will face higher infection rights' prices/Pigouvian taxes (per worker). The same is true for individuals featuring higher health treatment costs, who are richer and who make consumption-leisure choices with higher social dimension.

4.1.1 Production chains

The analysis of the informational advantage of markets for infection rights over command economy interventions is even clearer if we allow for production chains, that is, we introduce other goods that are produced (upstream) and are intermediate goods, used as input in the production of the single consumption commodity (downstream).

Following similar steps to those of the analysis in the previous section, it is straightforward to show that the decentralization of the Efficient allocation requires a single market for rights of infection at work, where firms in all sectors trade rights at the price q_h that has again the same expression as in (1). In this context, the equilibrium price of the intermediate good together with the price of infection rights induce both upstream and downstream firms to coordinate efficiently their production and abatement decisions without any informational requirement on the part of the policy maker.¹⁷ Thus we can say that no additional externality in contagion is generated by the presence of production chains.

4.2 Social preferences/constraints over infections

The decentralization result through markets for infection rights requires the policy maker to set the level of the supply of infection rights H_h , H_l at the efficient level, at which the social welfare function is maximized. The social welfare function we have studied in the previous section coincides with the representative agent's utility, that determines the preferences of society over consumption, leisure as well as infections. Consider instead the case in which social welfare, as far as the public health conditions of society are concerned, is represented by direct preferences over these conditions, in particular over the spread of the infection in the population. Suppose

¹⁷See the Appendix for details.

the socially preferred level of infections in the society is represented by I_h^*, I_l^* . In this case, the *Efficient allocation* is the one that maximizes the representative agent's utility subject to feasibility and the additional constraint that the level of infection (I_h, I_l) is equal to (I_h^*, I_l^*) . It is clear that the decentralization of this allocation as a competitive equilibrium requires no information on the parameters of the economy on the part of the policy maker.

An alternative interpretation of this specification is also possible. So far we assumed that unit health care costs are constant, equal to η , whatever the share of the population that is infected. In many situations however the policy maker faces a capacity constraint in the provision of treatment for infected, $(I_h, I_l) \leq (I_h^*, I_l^*)$, e.g., determined by the availability of hospital (or ICU) beds, and this may bind.

4.3 Moral hazard

In the market design considered in the previous sections each firm and each agent must acquire rights for the infections it generates. As a consequence, the observability of the individual values of I_h and I_l , that is of the probability of being infected at work and via his/her consumption-leisure choices, is required to implement and enforce the competitive equilibrium with infection rights. In this section we show that the decentralization of the Efficient allocation via markets for infection rights does not require this fine degree of observability at the individual level, only the observation of the average infection rate suffices.

Consider a society where only the health status of individuals is observable, but not where infections took place. Provided the number of individuals working in a firm is sufficiently large, we can say this captures the average value of the total probability of infection I of these individuals. Such limited observation generates a problem of *moral hazard* in teams, as in Holmstrom (1982), since both the choice of a by the firm employing agents and that of the level l of social interaction by each of these agents contribute to determine the (average) probability that they are infected.

We show in what follows that in this environment it is still possible to decentralize the Efficient allocation with markets for infection rights, provided we allow for lump sum taxes and subsidies not only for consumers but also for firms. Let I denote the average infection rate of agents working in a firm.¹⁸ The institutional market design introduced in Section 3 is then modified as follows.

Each agent engaging in consumption-leisure activities is mandated to buy - at the price q_h - a right per unit of probability of infection I;

¹⁸The argument and result can also be extended to the case where only the average probability of infection of an individual in the whole society is observed (that is, can be inferred from the available data).

- Each firm employing L_h workers is mandated to buy a right per infected worker, IL_h in total, at the unit price q_l .
- Not only the agent but also the firm pays a lump sum tax (receives a transfer if negative), given respectively by T and T_h .

Both the individual and the firm take into account how the value of I is affected, though only partly, by their own choices:

$$I = \gamma(1-a) + \sum_{i}^{L_h} \frac{\delta(l_i, \bar{l})}{L_h}.$$

Competitive equilibrium with infection rights and moral hazard. A Competitive equilibrium with infection rights and moral hazard is a competitive equilibrium with infection rights as previously defined, but i) the cost of infection rights for individuals and firms is given, respectively, by $q_l I$ and $q_h IL_h$; ii) the government chooses only the supply of total infection rights H; iii) the market clearing condition for infection rights is simply H = IL.

At the Competitive equilibrium with infection rights and moral hazard, total infections IL are equal to the level of the supply of rights H set by the government. It is now straightforward to prove that, when H is set equal to the efficient level of infections, the Efficient allocation is decentralized also in the presence of moral hazard:

Proposition (Efficiency of equilibria with moral hazard). Suppose the government chooses a supply of infection rights H equal to the Efficient level of infections in the society, IL. Then the Competitive equilibrium with infection rights and moral hazard induces the Efficient allocation.

The proof of the decentralization result with moral hazard develops along the same lines as the proof of Proposition (Efficiency of equilibrium). In fact, the price of infection rights for firms q_h supporting the efficient allocation is the same with and without moral hazard, given by (1). The only difference is that now a lump sum transfer to firms is required. This is due to the fact that each firm needs to acquire a greater amount of infection rights, IL_h rather than I_hL_h and so ends up paying also for the infections caused by its workers' decisions (that is, $\sum_{i=1}^{L_h} \delta(l_i, \bar{l})$). This additional payment operates as lump sum tax paid by the firm via its purchase of infection rights, which must be offset with a lump sum rebate for the same amount to keep the level of its profits unchanged.

In contrast, the price of infection rights faced by agents q_l in the presence of moral hazard is L times the one obtained before, (2). This is due to the fact that

with moral hazard each worker must acquire an amount of rights equal to the average infection rate among workers in the firm $\sum_{i}^{L} \frac{\delta(l_i, \bar{l})}{L}$, rather than to his/her individual infection rate $\delta(l_i, \bar{l})$. The agent's utility is only directly affected by the latter, but the agent ends up paying only a fraction 1/L of the infections generated by his/her chosen level of interaction. To preserve his/her incentives, the price of infection rights is then multiplied by L. Furthermore, the additional amount of rights the agent must purchase is determined by the interaction choices of other individuals working in the firm, $\sum_{j \neq i}^{L} \frac{\delta(l_j, \bar{l})}{L}$, as well as on the abatement decisions by the firm, I_h . The payment for these other amounts is then independent of the agent's own decisions, thus a constant for him/her, analogous to a lump sum tax, which must be rebated back to the individual by suitably increasing the value of -T above the level obtained in Proposition (Efficiency of equilibrium), in the case without moral hazard.

To sum up, in the situation considered moral hazard can be fully overcome and the incentives of firms and agents sustained simply by increasing the amount of infection rights they are required to purchase and possibly by suitably increasing the price of rights. Budget balance is then preserved with suitable lump sum rebates.

Finally, the Efficiency of equilibria with moral hazard extends to an economy which accounts for technological heterogeneity and multiple production as well as consumption-leisure sectors. That is, competitive equilibria with infection rights are efficient even if it is not observable whether agents are infected in a production or consumption-leisure activity nor, a fortiori, in which production or consumptionleisure activity.

4.4 Private information

We examine in what follows how the design of the markets for infections rights we considered (with fixed supply of rights), the variant of the design with fixed prices of these rights (or Pigouvian taxes) and the command economy fare in the presence of *private information* regarding the firm's productivity and/or the parameters capturing the infectiousness of production and consumption-leisure activities. More precisely we consider situations where these parameters are subject to *unanticipated* shocks, whose realization is known to the agents but not to the policy maker. The specification of the policy for the different interventions considered is set at the level which allows to attain the Efficient allocation prior to the realization of the shock.

In the case of the command economy intervention the values of a, l - and hence the allocation - are determined and cannot respond in any way to the realization of the shock. We have so a welfare loss. With a market for infection rights, when the policy maker fixes the quantity supplied (resp. the price) of these rights, this remains unchanged when the shock occurs but consumers' and firms' demand may vary and so prices (resp. quantities) adjust to clear. Hence the allocation obtained in equilibrium may still indirectly respond to the shock. Following the approach pioneered by Weitzman $(1974)^{19}$, we will evaluate and compare the welfare losses at the allocations obtained with the three distinct designs of policy interventions, relative to the Efficient allocation after the shock realization, for different kinds of shocks, determining so which intervention is preferable in terms of social welfare.

We evaluate first these effects for the firms' abatement level. Our findings²⁰ are summarized in the following:

Proposition (Welfare losses - abatement choice). The price setting design of infection rights induces, in the face of private information over the shocks to any of the parameters affecting the generation of infections γ , and the output and utility costs of infections $\eta, A, C(.), \beta$, an abatement choice which is preferable in terms of social welfare, at least weakly, to both to the command economy and the quantity setting designs.

Figure 1a illustrates the result for the case of shocks increasing labor productivity A. In the command economy and the quantity setting design the value of a remains unchanged after the shock. Hence there is a positive welfare loss. With the price setting (or Pigouvian tax) design, the equilibrium value of a changes to the level that is efficient after the shock realization, so there is no welfare loss.

Turning then to the agents' consumption-leisure choices, we have:

Proposition (Welfare losses - consumption-leisure choice). In the face of privately observed shocks to infection process $\delta(.)$ the quantity setting of infection rights designinduces lower welfare losses associated to the agents' consumption-leisure choice, for most parameter values, to both to the command economy and the price setting designs. In contrast, in the face of shocks to the utility costs of infections β , price setting is preferable.

Figure 1b describes the effects in the case of a shock decreasing the magnitude of the externality in infections in consumption-leisure activities $\partial \delta / \partial \bar{l}$. In the command economy and price setting design the agents' leisure choice remains unchanged, generating the welfare loss represented by the green shaded area. With the quantity setting design l instead varies, though less than at the optimum; the welfare loss is the (smaller) grid-patterned area.

Our findings thus show that the design of a market for infection rights allows to reduce, at least weakly, the welfare losses that we have with a command economy intervention due to shocks to parameter values of the economy that are only privately observed by individuals and firms. Furthermore, while the price setting design proves

¹⁹An interesting survey of a subsequent literature on the applications of the ideas in Weitzman (1974) to environmental control is Karp and Traeger (2018).

²⁰See the Appendix for details.

superior in the case of firms' abatement choices, this is not the case for agents' consumption-leisure choices.

Figure 1: Welfare losses with private information



(a) Firms' abatement choice, increase in firm's productivity



(b) Agents' leisure choice, decrease in externality in social interaction

Parameterization: $u(c,l) = \theta c + l - \frac{1}{2}\lambda l^2$, $C(a,1) = \frac{1}{2}ca^2$, L = 1, and $\delta(l,\bar{l}) = \delta_1 l + \delta_2 \bar{l}$. In Panel (a), \underline{A} is the initial value of firm's productivity and \underline{a} the associated efficient level of abatement; $A' > \underline{A}$ the value of productivity after the shock and a' the new efficient level of abatement as well as the new equilibrium with price setting. The color shaded area represents welfare losses for command economy and quantity setting designs. In Panel (b) $\underline{\delta_2}$ is the initial value of the externality in social interaction and \underline{l} the associated efficient level of consumption-leisure; $\delta'_2 < \underline{\delta_2}$ the value of the externality after the shock and l' the new efficient level of consumption-leisure and equilibrium with price setting. The color shaded area represents welfare losses for command economy and price setting. The color shaded area represents the smaller welfare loss with quantity setting when the equilibrium level changes to l''.

References

Acemoglu, D., V. Chernozhukov, I. Werning, and M. D Whinston (2020), "A Multi-Risk SIR Model with Optimally Targeted Lockdown," NBER Working Paper 27102.

Atkeson, A. (2020), "What Will Be the Economic Impact of COVID-19 in the US? Rough Estimates of Disease Scenarios," NBER Working Paper 26967

Alvarez, F.E., D. Argente, and F. Lippi (2020), "A Simple Planning Problem for COVID-19 Lockdown," NBER Working Paper 26981.

Argente, D.O., C-T Hsieh, and M. Lee (2020), "The Cost of Privacy: Welfare Effect of the Disclosure of COVID-19 Cases," NBER Working Paper 27220.

Arrow, K. J. (1969), "The organization of economic activity: Issues pertinent to the choice of market versus non-market allocation," in *The Analysis and Evaluation of Public Expenditures: The PPB System*, pp. 47-64, U.S. Congress, Joint Economic Committee, U.S. Government Printing Office, Washington, DC.

Baumol, W. J. (1972), "On Taxation and the Control of Externalities", *American Economic Review*, 62 (3), 307-322.

Bethune, Z. and A. Korinek (2020), "Covid-19 Infection Externalities: Pursuing Herd Immunity or Containment?" NBER Working Paper 27009.

Bisin, A. and P. Gottardi (2006), "Efficient Competitive Equilibria with Adverse Selection," *Journal of Political Economy*, 114(3), 485-516.

Bisin, A. and A. Moro (2020), "Learning Epidemiology by Doing: The Empirical Implications of a Spatial-SIR Model with Behavioral Responses," NBER Working Paper 27590.

Coase, R. H. (1960), "The Problem of Social Cost," *Journal of Law and Economics*, 3, 31–44.

Dales, J. H. (1968), *Pollution, Property and Prices: An Essay in Policy-making and Economics*, Toronto: University of Toronto Press.

Eichenbaum, M.S., S. Rebelo and M. Trabandt (2020), "The Macroeconomics of Epidemics," NBER Working Paper 26882.

Farboodi, M., G. Jarosch and Shimer, R. (2020), "Internal and external effects of social distancing in a pandemic," NBER Working Paper 27059.

Holmstrom, B. (1982), "Moral Hazard in Teams," *The Bell Journal of Economics*, 13 (2), 324-340.

Karp, L. and C. Traeger (2018), "Prices versus Quantities Revisited," mimeo, UC Berkeley.

Kaplan, G., B. Moll, and G. Violante (2020), "The Great Lockdown and the Big Stimulus: Tracing the Pandemic Possibility Frontier for the U.S.," mimeo, University of Chicago.

Lindahl, E. (1919), "Just Taxation: A Positive Solution" [Die Gerechtigkeit der Besteuring], in Musgrave, R. and A.T. Peacock, eds., (1958), *Classics in the Theory of Public Finance*, London: Macmillan.

Pigou, A. C. (1920), The Economics of Welfare, London: Macmillan.

Rowthorn, R. and F. Toxvaerd (2020), "The Optimal Control of Infectious Diseases Via Prevention and Treatment," Cambridge-INET W.P. 2020/13.

Toxvaerd, F. (2020), "Equilibrium social distancing," mimeo, University of Cambridge 2020.

Weitzman, M. (1974), "Prices versus Quantities," *Review of Economic Studies*, 41(4), 477-491.

Appendix: Definitions and Proofs

Competitive Equilibrium At a Competitive Equilibrium, i) each agent maximizes his/her utility, by choice of c, l, for given π , I_h , w, T, \overline{l} :

$$\max_{c,l} u(c,l) - \beta \left(I_l + I_h \right), \quad s.t.$$
(5)

$$c = \frac{\pi}{L} + w - T, \tag{6}$$

$$I_l = \delta(l, \bar{l}); \tag{7}$$

ii) each firm maximize profits by choice of a, L_h , for given w, I_l :

$$\max_{Y,a,L_h} \pi = Y - wL_h - C(a,L_h), \quad s.t.$$
(8)

$$Y = AL_h(1 - I_h - I_l), (9)$$

$$I_h = \gamma(1-a); \tag{10}$$

iii) the government balances the budget;

$$\eta(I_h + I_l)L = T; \tag{11}$$

iv) markets clear,

$$c = \frac{1}{L_h} \left[AL_h (1 - I_h - I_l) - C(a, L_h) - \eta (I_h + I_l) \right]$$
(12)

$$L_h = L \tag{13}$$

v) the externality in social interaction satisfies the consistency condition,

$$l = \bar{l}.\tag{14}$$

Efficient allocation. At the Efficient allocation, c, l, a maximize social welfare:

$$\max_{c,l,a} \qquad u(c,l) - \beta(I_l + I_h) \tag{15}$$

$$c = \frac{1}{L} \left[AL(1 - I_h - I_l) - C(a, L) - \eta (I_h + I_l)L \right]$$
(17)
(18)

where

s.t.

$$I_l = \delta(l, l) \tag{19}$$

$$I_h = \gamma(1-a) \tag{20}$$

Competitive equilibrium with infection rights. A Competitive equilibrium with infection rights is a competitive equilibrium as previously defined but:

the agent's budget constraint (previously Equation 6) is

$$c + q_l I_l = \frac{\pi}{L} + w - T; \tag{21}$$

the firm's objective (previously Equation 8) is:

$$Y - wL_h - q_h I_h L_h - C(a, L_h);$$

$$(22)$$

the government chooses the supply of infection rights H_l, H_h and its budget constraint is

$$\eta(I_h + I_l)L = T + q_h H_h + q_l H_l; \tag{23}$$

markets for infection rights also clear,

$$I_h L = H_h, \ I_l L = H_l. \tag{24}$$

Proof of Proposition: Efficiency of equilibrium - prices. The first order conditions of the social welfare maximization problem are:

$$\left[\frac{\partial u}{\partial c}(A+\eta) + \beta\right]\gamma = \frac{\partial u}{\partial c} \cdot \frac{C_1(a,L)}{L}$$
(25)

$$\left(\frac{\partial u}{\partial c}(\eta + A) + \beta\right)\delta'(l, l) = \frac{\partial u}{\partial l}$$
(26)

where $C_1(a, L)$ denotes the derivative of C with respect to its first argument, a, and - with some abuse of notation - $\delta'(l, l) \equiv \frac{\partial \delta(l, l)}{\partial l} + \frac{\partial \delta(l, l)}{\partial l}$, the total derivative of $\delta(l, \bar{l})$ w.r.t. l and \bar{l} , evaluated at $\bar{l} = l$. The first order condition for the firm's optimal abatement choice at the Competitive equilibrium with infection rights is instead

$$(A+q_h)\gamma L = C_1(a,L).$$
(27)

It is then immediate to verify that conditions (25) and (27) generate the same choice and allocation if q_h is set as in (1).

Consider then the first order condition with respect to l for the agent's maximization problem in the Competitive equilibrium with infection rights,

$$\frac{\partial u}{\partial l} = \left(\beta + \frac{\partial u}{\partial c}q_l\right)\frac{\partial\delta(l,\bar{l})}{\partial l}.$$
(28)

Conditions (26) and (28) support the same choice if $\left[\frac{\partial u}{\partial c}(\eta + A) + \beta\right] \delta'(l, l) = (\beta + \frac{\partial u}{\partial c}q_l)\frac{\partial \delta(l,\bar{l})}{\partial l}$; that is, if $q_l = (\eta + A)\frac{\delta'(l,l)}{\partial \delta(l,\bar{l})/\partial l} + \frac{\beta}{\partial u/\partial c}\left(\frac{\delta'(l,l)}{\partial \delta(l,\bar{l})/\partial l} - 1\right)$; which can be rewritten as in (2).

Finally, substituting the expressions obtained for the prices of infection rights into the government budget constraint (23), after some algebra, yields the expression of the lump sum tax T in (3). It is easy to see that both terms in (3) are negative, and hence that T has a negative sign.

4.5 Heterogenous agents

We focus our attention in this case on the Efficient allocation that maximizes utilitarian welfare, where all types of agents have the same welfare weight²¹. This is obtained as solution of the following programme:

$$\max_{\{c_i, l_i, a\}} \sum_{i}^{L} \left[u^i(c_i, l_i) - \beta_i (I_l^i + I_h) \right]$$
s.t.
$$\sum_{i}^{L} c_i = \left[AL(1 - \frac{\sum_{i}^{L} \left(I_h + I_l^i \right)}{L}) - C(a, L) - \eta(\frac{\sum_{i}^{L} \left(I_h + I_l^i \right)}{L}) L \right]$$

$$I_l^i = \delta^i(l_i, \frac{\sum_{f} l_f}{L}) \text{ for } i = 1, ..L$$

$$I_h = \gamma(1 - a)$$

The first order condition with respect to consumption-leisure for type i is then:²²

$$\frac{\partial u^i}{\partial l_i} = \left[\beta_i + (A + \eta_i)\frac{\partial u^i}{\partial c}\right]\frac{\partial \delta^i}{\partial l_i} + \left[\sum_f \left(\beta_f + (A + \eta_f)\frac{\partial u^i}{\partial c})\frac{1}{L}\frac{\partial \delta^f}{\partial \bar{l}}\right)\right]$$

Hence the effect of the externality in infections must be weighted with the heterogeneous utility and health care costs across individuals who get infected. The first order condition with respect to the choice of the same variable at a competitive equilibrium with infection rights is instead essentially the same as the one obtained with homogeneous agents, (28):

$$\frac{\partial u^i}{\partial l_i} = (\beta_i + \frac{\partial u^i}{\partial c} q_l^i) \frac{\partial \delta^i}{\partial l_i}$$

$$\xi^{i}\frac{\partial u^{i}}{\partial l_{i}} = \left[\xi^{i}\beta_{i} + (A+\eta_{i})\frac{\partial u^{i}}{\partial c}\xi^{i}\right]\frac{\partial\delta^{i}}{\partial l_{i}} + \left[\sum_{f}\left(\xi^{f}\beta_{f} + (A+\eta_{f})\frac{\partial u^{i}}{\partial c}\xi^{i}\right)\frac{1}{L}\frac{\partial\delta^{f}}{\partial \overline{l}}\right)\right]$$

hence we see that, because of the utility costs of getting infected, welfare weights matter.

²¹To focus on the effects of agents' heterogeneity on their consumption-leisure choices, we assume all firms are identical and so is the probability of getting infected at work for all agents.

²²Note that at an abitrary point on the welfare frontier, characterized by individual welfare weights ξ^i , the first order condition is

Hence the expression of the price supporting the efficient allocation is:

$$q_l^i = A + \eta_i + \frac{\sum_f (A + \eta_f) \frac{1}{L} \frac{\partial \delta^f}{\partial l}}{\frac{\partial \delta^i}{\partial l_i}} + \frac{\sum_f \beta_f \frac{1}{L} \frac{\partial \delta^f}{\partial l}}{\frac{\partial u^i}{\partial c} \frac{\partial \delta^i}{\partial l_i}}$$

Production Chains

Consider the following reformulation of the firm's production function

$$Y = AD^{\alpha}(L_y(1 - I_y - I_l))^{1-\alpha},$$

where Y is, as before, the output of the single consumption commodity in the economy, L_y is now the quantity of labor (number of workers, each working one unit) employed in the production of Y, D is the intermediate good used in the production of Y, I_y is the probability that a worker employed in the firm producing Y ends up being infected at work. The quantity D of the intermediate good is produced with labor,

$$D = BL_d(1 - I_d - I_l),$$

where L_d is the quantity of labor in the production of D, I_d is the probability of becoming infected at work for a worker employed in the firm producing D.²³ The infection rate of agents at work in the two sectors is, respectively, $I_y = \gamma_y(1 - a_y)$, $I_d = \gamma_d(1 - a_d)$, where a_y and a_d denote social distancing and other abatement measures the firms can employ, at (increasing convex) costs $C_y(a_y, L_y)$, $C_d(a_d, L_d)$, for the two production processes. The total number of agents infected at work is then $I = I_y L_y + I_d L_d$.

Following a similar procedure as in the proof of Proposition (Efficiency of Equilibrium), we compare the first order conditions of the firms at the equilibrium with those of the social optimum. In fact, to show that efficiency is obtained at an equilibrium with infection rights, it suffices to study the conditions determining the level of abatement in the consumption good (downstream) and intermediate good (upstream) production. The first order condition of the social welfare problem with respect to a_d is:

$$\left(\frac{\partial u}{\partial c}\eta + \beta\right)\gamma_d \frac{L_d}{L} + \rho B\gamma_d \frac{L_d}{L} = \frac{\partial u}{\partial c} \frac{C_{d,1}(a_d, L_d)}{L},$$

$$\Leftrightarrow \quad \left(\frac{\partial u}{\partial c}\eta + \beta + \rho B\right)\gamma_d = \frac{\partial u}{\partial c} \frac{C_{d,1}(a_d, L_d)}{L_d}$$

²³We continue assuming that the total quantity of labor in the economy, $L = L_y + L_d$, is given exogenously - pre-determined at the outbreak of the epidemic.

where ρ is the Lagrange multiplier of the constraint

$$\frac{D}{L} = B(\frac{L_d}{L} - \gamma_d(1 - a_d)\frac{L_d}{L} - \frac{L_d}{L}\delta l);$$

that is, the shadow price of the intermediate good. We then see this condition is satisfied at a competitive equilibrium, where the firms' optimality condition is

$$(q_h + pB)\gamma_d = \frac{C_{d,1}(a_d, L_d)}{L_d}$$

when

$$p = \frac{\rho}{\frac{\partial u}{\partial c}}, \quad q_h = \eta + \frac{\beta}{\frac{\partial u}{\partial c}};$$

as in the one sector model.

Turning then to the upstream firms, the first order condition of the social welfare problem with respect to a_y is:

$$\left(\frac{\partial u}{\partial c}\eta + \beta\right)\gamma_y\frac{L_y}{L} + \frac{\partial u}{\partial c}\gamma_y\frac{L_y}{L}A(1-\alpha)D^{\alpha}(L_y - I_y - \frac{L_y}{L}I_lL)^{-\alpha} = \frac{\partial u}{\partial c}\frac{C_{y,1}(a_y, L_y)}{L}$$

while the analogous condition for a firm's optimum at a competitive equilibrium is:

$$q_h \gamma_y + \gamma_y A(1-\alpha) D^{\alpha} (L_y - I_y - \frac{L_y}{L} I_l L)^{-\alpha} = \frac{\partial u}{\partial c} \frac{C_{y,1}(a_y, L_y)}{L_y}$$

We see the solution of the two equations is the same when q_h takes the same value as above.

4.6 Moral Hazard

Competitive equilibrium with infection rights and moral hazard. A Competitive equilibrium with infection rights and moral hazard is a competitive equilibrium with infection rights as previously defined, except for the following facts:

the agent's budget constraint is now given by

$$c + q_l I = \pi + w - T \tag{29}$$

the firm's objective is now

$$y - wL_h - q_h IL_h - C(a, L_h) - T_h.$$
 (30)

the government chooses the supply of infection rights H;

both the individual and the firm take into account that

$$I = \gamma(1-a) + \sum_{i}^{L_h} \frac{\delta(l_i, \bar{l})}{L_h}.$$
(31)

and the market clearing condition for infection rights is

$$H = IL. \tag{32}$$

Proof of Proposition: Efficiency of equilibria with moral hazard. Consider the first order condition for the firm's choice of abatement at a competitive equilibrium in the current environment. Substituting the market clearing conditions for infection rights, (32), as well as for labor and the consumption good yields:

$$(A+q_h)\gamma L = C_1(a,L),$$

the same expression as the one obtained in the previous section, where I_h is observable (with no moral hazard). It then follows that the value of q_h inducing the optimal choice of a is unchanged. However each firm needs to acquire a greater amount of infection rights, IL_h rather than I_hL_h . To keep its net payments the same a lump sum rebate is thus needed.

The first order condition for the worker's optimal choice of leisure/social interaction at a competitive equilibrium, after substituting the market clearing conditions, is instead:

$$\left(\beta + \frac{\partial u}{\partial c}q_l\frac{1}{L}\right)\frac{\partial \delta}{\partial l} = \frac{\partial u}{\partial l}$$

It differs from the one obtained in the previous section for the fact that q_l is now multiplied by 1/L. To be able to still match the FOC's for a Pareto optimum, q_l must then be L times its value in the absence of moral hazard. This feature, together with the fact that in equilibrium each agent must also acquire a greater amount of infection rights, equal to $I_l + I_h$ instead of I_l , requires a higher value of the lump sum rebate received by agents, to offset the extra payment made by them.

Welfare losses wih unobserved shocks

We study the welfare losses associated to the following institutional designs of the policy interventions:

Command economy The government mandates a and l at the Efficient level prior to the parameter shock; the levels of a, l remain then unchanged after the shock.

- Quantity setting of infection rights The government sets the level of the supply H_h, H_l of infection rights equal to the Efficient level of infections prior to the parameter shock, that is, the infections induced by the Efficient allocation; after the shock, in a Competitive equilibrium with infection rights firms and individuals choose a, l facing prices q_h, q_l such that markets clear when the supply of rights remains fixed.
- **Price setting of infection rights** The government sets the prices of infection rights at the level q_h, q_l corresponding to the value at the Competitive equilibrium with infection rights prior to the parameter shock; after the shock, firms and individuals choose a, l facing an unchanged value of these prices, while the government supplies all requested infection rights so as to clear the market.

As in Weitzman (1974), we take a quadratic approximation to the agents' utility function as well as to the cost of abatement function in order to evaluate welfare losses. Since the social welfare maximization problem in our society is twodimensional, entailing the choice of l and a, we simplify further the analysis by considering in particular the case where the agents' utility is linear in consumption. Therefore, we have $u(c,l) = \theta c + l - \frac{1}{2}\lambda l^2$ and $C(a,1) = \frac{1}{2}ca^2$. Furthermore, we assume for simplicity (without any substantial loss of generality) that L = 1 and $\delta(l,\bar{l}) = \delta_1 l + \delta_2 \bar{l}$. Under these assumptions it is possible to evaluate the welfare losses at the allocations obtained with the three distinct designs of policy interventions relative to the Efficient allocation after the shock realization.

Specifically, we concentrate on shocks to parameters affecting the generation of infections, γ , δ_1 , δ_2 , and to parameters affecting the costs of infections, in terms of output and utility losses, η , A, c, β . Under the above assumptions, both the Efficient and the equilibrium levels of a and l are determined independently by a separate equation and hence the effects of shocks can be analyzed separately for each of the two variables. Results can be illustrated using diagrams analogous to the ones in Karp and Traeger (2018); see Figure 1.

4.6.1 Firms' abatement choice - Figure 1(a).

Under the assumptions stated in Section 4.4, the component of the representative consumer's utility that is affected by the abatement choice is given by

$$\theta a \gamma (A+\eta) + \beta \gamma a - \theta \frac{c}{2} a^2$$

Under the above assumptions, the first order condition of the social welfare maximization problem with respect to firms' abatement choice a, (equation 25), simplifies to:

$$ca\theta = \beta\gamma + \theta\gamma(A + \eta), \tag{33}$$

Equation (33) determines the efficient level of the firm's abatement choice a. The term on the left-hand-side of this equation describes the marginal cost of abatement, while the term on the right-hand-side describes the marginal benefit, in terms of direct utility gains and of the utility of the output gains, both due to the reduction of infections at work induced by a marginal increase in a.

Substituting into the above expression of the component of the consumer's utility the socially efficient value of a, obtained from (33), yields

$$\theta \frac{c}{2} \left(\frac{\theta \gamma (A + \eta) + \beta \gamma}{c \theta} \right)^2,$$

which describes then the welfare gain due to the efficient choice of a.

Consider first the **command economy intervention**. In this design, the policy maker mandates a at the efficient level prior to any shock, that is, the one which solves (33) for the values of the parameters before a shock occurs. A shock to any of the parameters γ , η , A, c, β however changes the efficient level of a. In the case of a command economy intervention, a is kept constant - in the face of parameter shocks - at the value $\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)$, given by the solution of (33) prior to any parameter shock. When any of γ , c, η , A, β changes, there is a positive welfare loss (relative to the efficient value of the welfare gain computed above, captured by

$$\theta \frac{c}{2} \left[\left(\frac{\theta \gamma (A+\eta) + \beta \gamma}{c \theta} \right)^2 \right] - \left(\theta \gamma (A+\eta) + \beta \gamma \right) \left(\frac{\overline{\theta \gamma (A+\eta) + \beta \gamma}}{c \theta} \right) + \theta \frac{c}{2} \left(\frac{\overline{\theta \gamma (A+\eta) + \beta \gamma}}{c \theta} \right)^2$$

$$= \theta \frac{c}{2} \left[\left(\frac{\theta \gamma (A+\eta) + \beta \gamma}{c \theta} \right)^2 - 2 \left(\frac{\theta \gamma (A+\eta) + \beta \gamma}{c \theta} \right) \left(\frac{\overline{\theta \gamma (A+\eta) + \beta \gamma}}{c \theta} \right) + \left(\frac{\overline{\theta \gamma (A+\eta) + \beta \gamma}}{c \theta} \right)^2 \right]^2$$

$$= \theta \frac{c}{2} \left[\left(\frac{\theta \gamma (A+\eta) + \beta \gamma}{c \theta} \right) - \left(\frac{\overline{\theta \gamma (A+\eta) + \beta \gamma}}{c \theta} \right) \right]^2$$

If for instance the value of A after the shock increases from \underline{A} to $A' > \underline{A}$, as in panel (a) of Figure 1, then the efficient abatement level also increases to the value a' solving $ca'\theta = \beta\gamma + \theta\gamma(A' + \eta)$.²⁴ We have so a positive welfare loss in the case of a command economy intervention, represented by the red shaded area in the figure. The same is true in the case of shocks to any of other parameters γ, η, c, β .

Consider in turn the design given by **quantity setting** of infection rights. The policy maker sets the supply of rights H_h at the efficient level of infections at work prior to the shock, equal to $I_h L = \gamma(1-a)L$, obtained from equations (10) and (24),

²⁴In the figure, a' is obtained at the intersection between the new horizontal dashed line (in red), describing the new level of the marginal benefits of abatement, and the unchanged positively sloped line, describing the marginal cost of abatement.

with a determined by the solution of (33). In the case of quantity setting, that is when H_h is set at the value $\bar{H}_h = LI_h = \gamma \left[1 - \left(\frac{\bar{\theta}\gamma(A+\eta) + \beta\gamma}{c\theta}\right)\right] L$, the welfare loss is the same as with a command economy intervention, except when we have a shock to γ , say $\gamma' > \gamma$. When that happens, the constant level \bar{H}_h of the supply of rights induces a change in the value of a, to a' such that:

$$\gamma'(1-a') = \gamma \left[1 - \left(\frac{\overline{\theta\gamma(A+\eta) + \beta\gamma}}{c\theta}\right)\right].$$

Hence

$$a' = \left(1 - \frac{\gamma}{\gamma'}\right) + \frac{\gamma}{\gamma'}\left(\frac{\overline{\theta\gamma(A+\eta) + \beta\gamma}}{c\theta}\right) > \left(\frac{\overline{\theta\gamma(A+\eta) + \beta\gamma}}{c\theta}\right),$$

that is the equilibrium value of a increases in response to the increase in γ , as does the Efficient value. Furthermore, the magnitude of the increase of the equilibrium value of a may be greater than that of the efficient response:

$$\left(1-\frac{\gamma}{\gamma'}\right)+\frac{\gamma}{\gamma'}\left(\frac{\overline{\theta\gamma(A+\eta)+\beta\gamma}}{c\theta}\right)>\frac{\gamma'}{\gamma}\left(\frac{\overline{\theta\gamma(A+\eta)+\beta\gamma}}{c\theta}\right)$$

satisfied if and only if $\frac{\gamma}{\gamma'+\gamma} > \left(\frac{\overline{\theta\gamma(A+\eta)+\beta\gamma}}{c\theta}\right)$. Recalling that at an interior optimum a < 1, we see that this inequality holds for some parameter values. Hence we may have overshooting in equilibrium.

Hence with quantity setting of infection rights we still have a welfare loss. Since we may have overshooting, it is possible that the welfare loss is greater than with the command economy intervention. This happens if and only if:

$$\begin{split} &\theta_{2}^{c}\left[\left(\overline{\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}}\right)-\frac{\gamma'}{\gamma}\left(\overline{\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}}\right)\right]^{2} < \theta_{2}^{c}\left[\left(\left(1-\frac{\gamma}{\gamma'}\right)+\frac{\gamma}{\gamma'}\left(\overline{\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}}\right)\right)-\frac{\gamma'}{\gamma}\left(\overline{\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}}\right)\right]^{2} \\ &\Leftrightarrow \left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)^{2}-2\frac{\gamma'}{\gamma}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)^{2} < . \\ &< \left(\left(1-\frac{\gamma}{\gamma'}\right)+\frac{\gamma}{\gamma'}\left(\overline{\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}}\right)\right)^{2}-2\frac{\gamma'}{\gamma}\left(\left(1-\frac{\gamma}{\gamma'}\right)+\frac{\gamma}{\gamma'}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)\right)\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) \\ &\Leftrightarrow 2\frac{\gamma'}{\gamma}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)\left(\left(1-\frac{\gamma}{\gamma'}\right)+\frac{\gamma}{\gamma'}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)-\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)\right) < \\ &< \left(\left(1-\frac{\gamma}{\gamma'}\right)+\frac{\gamma}{\gamma'}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)\right)^{2}-\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)^{2} \\ &\Leftrightarrow 2\frac{\gamma'}{\gamma}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) < \left(\left(1-\frac{\gamma}{\gamma'}\right)+\frac{\gamma}{\gamma'}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right)\right) + \left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) \\ &\Leftrightarrow \frac{\gamma'}{\gamma}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) - \left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) < \left(1-\frac{\gamma}{\gamma'}\right) + \frac{\gamma}{\gamma'}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) - \frac{\gamma'}{\gamma}\left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) \\ &\Leftrightarrow \left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) - \left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) < \left(1-\frac{\gamma}{\gamma'}\right) \\ &\Leftrightarrow \left(\frac{\theta\gamma(A+\eta)+\beta\gamma}{c\theta}\right) < 2\frac{\gamma'(\gamma'-\gamma)}{\gamma'} - 1 - \frac{\gamma}{\gamma'}\right) < \left(1-\frac{\gamma}{\gamma'}\right) \end{aligned}$$

that is when we have a sufficiently large overreaction with quantity setting. It then follows that, except when the overshooting is sufficiently large, the quantity setting design is socially preferable to the command economy intervention.

Consider finally the **price setting** of infection rights design. The policy maker sets the price of infection rights for the firm at the level $q_h = \eta + \beta/\theta$, that is, so as to satisfy equation (1),²⁵ the expression for the equilibrium price of these rights derived in Proposition (Efficiency of equilibrium - prices), which supports the Efficient allocation prior to any shock. We then see from the condition for the firms' optimal choice of *a* in a competitive equilibrium, (27), that in response to any shock to the parameters γ , *A*, *c*, when q_h is kept constant the equilibrium value of *a* changes to the level that is efficient after the shock realization.²⁶ We see in fact from (1) that the level of the price supporting the Efficient allocation after shocks to these parameters is unchanged. Hence there is no welfare loss associated to this design.

On the other hand, we readily see from (27) that the firms' choice of a in equilibrium remains unchanged after shocks to η , β ,²⁷ so that in this case the welfare loss is

²⁵When the marginal utility for consumption is constant and equal to θ .

²⁶For instance, in Figure 1(a) the equilibrium value of the abatement choice after the shock equals the new efficient level a'.

²⁷Recall that we do not consider preference shocks to the marginal utility of consumption, θ , as

positive and equal to the loss associated to the command economy and the quantity setting designs.

4.6.2 Agents' consumption-leisure choice - Figure 1(b).

The efficient level of the agents' consumption-leisure choice l is obtained as a solution of the first order condition of the social welfare maximization problem with respect to l, (equation (26)), which under the above assumptions simplifies to:

$$1 - \lambda l = \beta \left(\delta_1 + \delta_2\right) + \theta (A + \eta) \left(\delta_1 + \delta_2\right). \tag{34}$$

The analysis of the welfare losses associated to the value of l obtained for the three designs for policy interventions follows the logic of the analysis we carried out for firms' abatement choices.

In the **command economy** design the policy maker sets l to solve (34) prior to the shock. Hence, for shocks to any of the variables $\delta_1, \delta_2, \eta, A, \beta$ we have a positive welfare loss. Figure 1(b) describes the case of a decrease in δ_2 , and the welfare loss due to the fact that agents' leisure choice remains unchanged in response to these shocks is represented by the green shaded area.

In the **quantity setting** design the policy maker sets the supply of rights H_l at the level $I_l L = (\delta_1 + \delta_2) lL$ (from equations (14) and (24)), with l determined by (34) before the shock occurs. It is immediate to verify that, as we saw for the abatement choice, when we have a shock to the production or preference parameters (η, A, β) the equilibrium value of l remains unchanged and so the welfare losses are the same as for the command economy. When instead a shock to the parameters of the infection technology δ_1, δ_2 occurs, with quantity setting the equilibrium value of l varies; again the change is in the same direction as the change of the efficient level²⁸ and, for some parameter values, we have an over-reaction, that is the magnitude of the equilibrium variation is greater than the one required for efficiency. Figure 1(b) describes a situation in which we have under-reaction in response to a decrease in δ_2 : the new equilibrium level with quantity setting is²⁹ l'' and the welfare loss is the (smaller) grid-patterned area.

Finally, in the **price setting** design the policy maker sets q_l at the level $\left[(\eta + A)\frac{\delta_1 + \delta_2}{\delta_1} + \frac{\beta}{\theta}\frac{\delta_2}{\delta_1}\right]$, which satisfies equation (2) derived in Proposition (Efficiency of equilibrium - prices). The change in the equilibrium level of l in response to shocks

they do not refer to the direct effects of infections. It can be shown however that for such shocks the equilibrium value of a in the price setting design remains unchanged, as in the command economy and the quantity setting designs. Hence the welfare loss is the same in all these cases.

²⁸If, say δ_1 increases to δ'_1 , the new equilibrium value of l'' satisfies $(\delta'_1 + \delta_2)l'' = (\delta_1 + \delta_2)l$; hence it decreases, as the efficient value, obtained from (34), does.

²⁹The value of l'' is obtained as a solution of the equation: $(\delta_1 + \delta_2)l = (\delta_1 + \delta'_2)l''$.

is then obtained from the first order condition for an individual optimum (28) when q_l is kept constant at the set level. It is immediate to verify that the welfare losses associated to this design (for shocks to $\delta_1, \delta_2, \eta, A, \beta$) are now also always positive. They are smaller than the losses associated to the command economy and the quantity setting designs for shocks to β , while they are equal for shocks to η, A . In the first case, in fact, the equilibrium value of l varies in the same direction, in response to a shock, though by a smaller amount, than the efficient value. In the second case, instead, the equilibrium value l does not vary. On the other hand, in the case of shocks to δ_2 (the situation considered in Figure 1(b)) we have no change in l in the price setting design, as for the command economy, while we do have a change in l in the quantity setting design. We show below that, for a large set of parameter values, the welfare loss is smaller in the latter case (this is the case in Figure 1(b)).

Finally, the ranking of the welfare losses with respect to shocks to δ_1 complex. This is because the equilibrium change in l in the price setting design is in the same direction but larger than required by efficiency ex-post, that is we have always an over-reaction; while in the quantity setting design, as noticed in the previous paragraph, it can be either larger or smaller. We show below that again for a large set of parameter values the welfare loss is smaller in the quantity setting design.

Shocks to δ_1, δ_2 : Quantity vs. Price setting of infection rights The supply of infection rights H_l is fixed at the level $I_l L = (\delta_1 + \delta_2) \underline{l} L$, with \underline{l} satisfying $1 - \lambda \underline{l} = \beta (\delta_1 + \delta_2) + \theta (A + \eta) (\delta_1 + \delta_2)$. When $\delta_1 + \delta_2$ increases, say by an infinitesimal amount ε , the equilibrium value of l, which we obtain from the equation $(\delta_1 + \delta_2 + \varepsilon)(\underline{l} + \Delta l)L = \overline{H}_l$, must decrease (by $(\delta_1 + \delta_2)\Delta l = -\varepsilon \underline{l})$. To find the change in the efficient level of l in response to the shock, observe that the right hand side of the FOC for an optimum (34) increases by $[\beta + \theta(A + \eta)] \varepsilon$, which means that $1 - \lambda l$, the term on the left-hand-side, should also increase by this amount, or $\Delta l = -[\beta + \theta(A + \eta)] \varepsilon/\lambda$. Comparing the two we see that the magnitude of the change in equilibrium is smaller than at the optimum iff

$$\frac{\varepsilon \underline{l}}{\delta_1 + \delta_2} < \varepsilon \frac{\beta + \theta(A + \eta)}{\lambda}$$

$$\frac{l\lambda}{\delta_1 + \delta_2} < (\beta + \theta(A + \eta)) (\delta_1 + \delta_2)$$

$$1 - \beta (\delta_1 + \delta_2) + \theta(A + \eta) (\delta_1 + \delta_2) < (\beta + \theta(A + \eta)) (\delta_1 + \delta_2)$$

$$\underline{l\lambda} < 1/2$$

$$(35)$$

At an interior solution we have $\underline{l}\lambda = 1 - (\beta + \theta(A + \eta))(\delta_1 + \delta_2) < 1$ so the above inequality may or may not be satisfied. We have so an over reaction when $1 - (\beta + \theta(A + \eta))(\delta_1 + \delta_2) > 1/2$, or $1/2 > (\beta + \theta(A + \eta))(\delta_1 + \delta_2)$.

 $(\beta + \theta(A + \eta)) (\delta_1 + \delta_2) > 1/2, \text{ or } 1/2 > (\beta + \theta(A + \eta)) (\delta_1 + \delta_2).$ To find the effect of fixing prices at the level $\bar{q}_l = \left[(\eta + A) \frac{\delta_1 + \delta_2}{\delta_1} + \frac{\beta}{\theta} \frac{\delta_2}{\delta_1} \right]$ we need to consider the first order condition for an individual optimum (28)

$$1 - \lambda l = (\beta + \theta \bar{q}_l) \delta_1$$

with the price set at the level \bar{q}_l . We then see that in the case of shocks of η , A, δ_2 the equilibrium value of l is unchanged, hence the welfare loss is the same as in the command economy. On the other hand, when δ_2 changes we saw above that with the quantity setting design l changes. By a similar argument as in the case of the abatement choice, we can say that the welfare loss is smaller in the quantity setting design than in the command economy or price setting designs (with no change in l) if

$$\left(\frac{l}{\delta_{1}+\delta_{2}}-\frac{\beta+\theta(A+\eta)}{\lambda}\right)^{2} < \left(\frac{\beta+\theta(A+\eta)}{\lambda}\right)^{2} \qquad (36)$$

$$\left(\frac{l}{\delta_{1}+\delta_{2}}\right)^{2} < 2\frac{l}{\delta_{1}+\delta_{2}}\frac{\beta+\theta(A+\eta)}{\lambda}$$

$$1-\left(\beta+\theta(A+\eta)\right)\left(\delta_{1}+\delta_{2}\right) < 2\left[\beta+\theta(A+\eta)\right]\left(\delta_{1}+\delta_{2}\right)$$

$$1 < 3\left(1-l\lambda\right) = 3\left[\beta+\theta(A+\eta)\right]\left(\delta_{1}+\delta_{2}\right)$$

Note that if (35) holds, (36) holds as well, which means that if the magnitude of the change when the supply of infection rights is fixed is smaller than at the optimum (under reaction, though in the 'right' direction), then the welfare loss is smaller in that case. This means that in order to have a smaller welfare loss with no change in l than with the one induced by fixed supply, we must an over -reaction with fixed supply, and a sufficiently big one.

When instead we have an (infinitesimal) change in δ_1 , the equilibrium value of l in the price setting design varies, by the amount $-(\theta \bar{q}_l + \beta)/\lambda = -(\beta (\delta_1 + \delta_2) + \theta (A + \eta) (\delta_1 + \delta_2))/\delta_1 \lambda$. In this case we have that the magnitude of the change of l in equilibrium is always greater than at the optimum (over-reaction) since

$$\frac{(\beta(\delta_1+\delta_2)+\theta(A+\eta)(\delta_1+\delta_2))}{\delta_1\lambda} > \frac{\beta+\theta(A+\eta)}{\lambda}$$

$$\Leftrightarrow \beta (\delta_1+\delta_2) + \theta(A+\eta) (\delta_1+\delta_2) > \delta_1 (\beta+\theta(A+\eta))$$

$$\Leftrightarrow \beta (\delta_2) + \theta(A+\eta) (\delta_2) > 0$$

always holds. Comparing then the welfare losses in the quantity setting and the

price setting designs, they are smaller in the first case if

$$\begin{split} \left(\frac{l}{\delta_{1}+\delta_{2}}-\frac{\beta+\theta(A+\eta)}{\lambda}\right)^{2} &< \left(\frac{(\beta(\delta_{1}+\delta_{2})+\theta(A+\eta)(\delta_{1}+\delta_{2}))}{\delta_{1}\lambda}-\frac{\beta+\theta(A+\eta)}{\lambda}\right)^{2} \\ &\left(\frac{\lambda l-[\beta+\theta(A+\eta)](\delta_{1}+\delta_{2})}{(\delta_{1}+\delta_{2})\lambda}\right)^{2} &< \left(\frac{(\beta(\delta_{1}+\delta_{2})+\theta(A+\eta)(\delta_{1}+\delta_{2}))-\delta_{1}(\beta+\theta(A+\eta))}{\delta_{1}\lambda}\right)^{2} \\ &\left(\frac{1-2[\beta+\theta(A+\eta)](\delta_{1}+\delta_{2})}{(\delta_{1}+\delta_{2})\lambda}\right)^{2} &< \left(\frac{\delta_{2}(\beta+\theta(A+\eta))}{\delta_{1}\lambda}\right)^{2} \\ &\left(1-2\left[\beta+\theta(A+\eta)\right](\delta_{1}+\delta_{2})\right)^{2}(\delta_{1})^{2} &< \left(\delta_{2}\left(\beta+\theta(A+\eta)\right)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2}+4\left[\beta+\theta(A+\eta)\right]^{2}(\delta_{1}+\delta_{2})^{2}(\delta_{1})^{2}-4\left(\delta_{1}\right)^{2}\left[\beta+\theta(A+\eta)\right](\delta_{1}+\delta_{2}) &< \\ &< \left(\delta_{2}\right)^{2}(\beta+\theta(A+\eta))^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2}+[\beta+\theta(A+\eta)]^{2}(\delta_{1}+\delta_{2})^{2}\left[4\left(\delta_{1}\right)^{2}-\left(\delta_{2}\right)^{2}\right] &< 4\left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2} &< \left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2} &< \left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2} &< \left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2} &= \left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2} &< \left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2} &= \left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\left(\delta_{1}\right)^{2} &< \left(\beta+\theta(A+\eta)\right)^{2}(\delta_{1}+\delta_{2})^{2} \\ &\leq \left(\beta+\theta(A+\eta)\right)^{$$

When the quantity setting design is superior to command economy (where there is no change), that is when $(\beta + \theta(A + \eta)) (\delta_1 + \delta_2) > 1/3$, the above condition can be written as

$$13(\delta_1)^2 < [4 + (\delta_2)^2]$$

always satisfied when $\delta_1, \delta_2 < 1/2$. Hence under these conditions we conclude that welfare losses are minimal in the quantity setting design.